Clinical trials
Observational Asthma trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Unknown status | 5 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bispebjerg Hospital | 7 |
| AstraZeneca | 4 |
| ALK-Abelló A/S | 1 |
| Aarhus University Hospital | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Chiesi Pharma AB, Nordic | 1 |
| Christiane Haase | 1 |
| Copenhagen University Hospital, Hvidovre | 1 |
| Elisabeth Juul Gade | 1 |
| Glostrup University Hospital, Copenhagen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asthma | 24 |
| Hypersensitivity | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Lung Diseases | 2 |
| Arthritis | 1 |
| Birth Weight | 1 |
| Bronchiectasis | 1 |
| Cardiovascular Diseases | 1 |
| Congenital, Hereditary, and Neonatal Diseases and Abnormalities | 1 |
| Cough | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.